BRISK-FL
Regimen
- Experimental
- brivanib 800 mg daily
- Control
- sorafenib
Population
Unresectable advanced hepatocellular carcinoma, no prior systemic therapy
Key finding
mOS 9.5 brivanib vs 9.9 sora (HR 1.06, 95.8% CI 0.93-1.22); **noninferiority NOT met** (margin ≤1.08 exceeded); brivanib failed as 1L option despite promising phase 2
Source: PMID 23980084